17
Jul 2026
New ctDNA blood test improves personalized prostate cancer treatment
A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most likely to benefit from 223Ra radiopharmaceutical therapy and monitor their progress throughout treatment, according to new research published in the July issue of The Journal of Nuclear Medicine.